Patents by Inventor Yukiko Yamagishi
Yukiko Yamagishi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11746332Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The high-purity renal progenitor cells can be used in regenerative medicine for renal diseases, such as renal failure.Type: GrantFiled: June 25, 2020Date of Patent: September 5, 2023Assignees: Astellas Pharma Inc., Kyoto UniversityInventors: Tatsuya Kawamoto, Yukiko Yamagishi, Kenji Osafune
-
Patent number: 11225642Abstract: The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGF? signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells.Type: GrantFiled: June 11, 2014Date of Patent: January 18, 2022Assignees: Kyoto University, Astellas Pharma Inc.Inventors: Kenji Osafune, Takafumi Toyohara, Yukiko Yamagishi
-
Publication number: 20200407692Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The disclosed method may include, for example, the steps of: (i) culturing the pluripotent stem cells under conditions that induce differentiation into renal progenitor cells; and (ii) sorting a cell population from the cells obtained at step (i), by using at least one cell surface marker selected from the group consisting of CD9(?), CD55(?), CD106(+), CD140a(+), CD140b(+), CD165(+), CD271(+) and CD326(?).Type: ApplicationFiled: June 25, 2020Publication date: December 31, 2020Applicants: Astellas Pharma Inc., KYOTO UNIVERSITYInventors: Tatsuya Kawamoto, Yukiko YAMAGISHI, Kenji OSAFUNE
-
Patent number: 10731133Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The disclosed method may include, for example, the steps of: (i) culturing the pluripotent stem cells under conditions that induce differentiation into renal progenitor cells; and (ii) sorting a cell population from the cells obtained at step (i), by using at least one cell surface marker selected from the group consisting of CD9(?), CD55(?), CD106(+), CD140a(+), CD140b(+), CD165(+), CD271(+) and CD326(?).Type: GrantFiled: September 9, 2016Date of Patent: August 4, 2020Assignees: Astellas Pharma Inc., Kyoto UniversityInventors: Tatsuya Kawamoto, Yukiko Yamagishi, Kenji Osafune
-
Publication number: 20180273905Abstract: An object of the present invention resides in providing a method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. A method for producing renal progenitor cells into which pluripotent stem cells are induced to differentiate, the method comprising the steps of: (i) culturing the pluripotent stem cells under conditions that induce differentiation into renal progenitor cells; and (ii) sorting a cell population from the cells obtained at step (i), by using at least one cell surface marker selected from the group consisting of CD9(?), CD55(?), CD106(+), CD140a(+), CD140b(+), CD165(+), CD271(+) and CD326(?).Type: ApplicationFiled: September 9, 2016Publication date: September 27, 2018Applicants: Astellas Pharma Inc., KYOTO UNIVERSITYInventors: Tatsuya KAWAMOTO, Yukiko YAMAGISHI, Kenji OSAFUNE
-
Publication number: 20160137985Abstract: The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGF? signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells.Type: ApplicationFiled: June 11, 2014Publication date: May 19, 2016Applicants: KYOTO UNIVERSITY, ASTELLAS PHARMA INC.Inventors: Kenji Osafune, Takafumi TOYOHARA, Yukiko YAMAGISHI
-
Patent number: 8252895Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.Type: GrantFiled: July 21, 2010Date of Patent: August 28, 2012Assignee: Astellas Pharma Inc.Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
-
Patent number: 7872097Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.Type: GrantFiled: October 26, 2006Date of Patent: January 18, 2011Assignee: Astellas Pharma Inc.Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
-
Publication number: 20100286033Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.Type: ApplicationFiled: July 21, 2010Publication date: November 11, 2010Inventors: Masahiro NEYA, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
-
Publication number: 20090170755Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.Type: ApplicationFiled: October 26, 2006Publication date: July 2, 2009Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi